Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-25-035155
Filing Date
2025-04-15
Accepted
2025-04-15 16:48:39
Documents
18
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm252518-1_pre14a.htm   iXBRL PRE 14A 1153277
6 GRAPHIC px_25maxcyteproxy1pg01-bw.jpg GRAPHIC 379419
7 GRAPHIC px_25maxcyteproxy2pg01-4c.jpg GRAPHIC 178617
  Complete submission text file 0001104659-25-035155.txt   3036930

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mxct-20241231.xsd EX-101.SCH 9636
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mxct-20241231_def.xml EX-101.DEF 2361
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mxct-20241231_lab.xml EX-101.LAB 34811
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mxct-20241231_pre.xml EX-101.PRE 3939
20 EXTRACTED XBRL INSTANCE DOCUMENT tm252518-1_pre14a_htm.xml XML 22541
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40674 | Film No.: 25840187
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)